Iovance Biotherapeutics (IOVA) News Today

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares have trended lower as investors digest second-quarter results that fell short of expectations, analyst price-target cuts and a voluntary withdrawal of the EU filing for its lead TIL therapy, Amtagvi. Key developments from the past 24–36 hours include:

• Positive Sentiment: Company reports $60.0 million in 2Q25 product revenue, treats over 100 patients with Amtagvi and, after a strategic restructuring, extends its cash runway into 4Q26 while reiterating FY 2025 revenue guidance of $250 million–$300 million. GlobeNewswire
• Neutral Sentiment: Full Q2 2025 earnings call transcript is now available, offering detailed management commentary on sales performance and clinical milestones. Seeking Alpha
• Neutral Sentiment: Chardan Capital reduces its price target from $25.00 to $20.00 but maintains a “Buy” rating, implying significant upside from current levels. Benzinga
• Negative Sentiment: Q2 results miss consensus: a loss of $0.33 per share versus an expected $0.29 loss, and revenue of $59.95 million versus $67.14 million estimate. MarketBeat Press Release
• Negative Sentiment: Wells Fargo cuts its price target from $18.00 to $14.00 despite keeping an “Overweight” rating, reflecting tempered expectations. MSN
• Negative Sentiment: Voluntary withdrawal of the EMA filing for Amtagvi raises regulatory uncertainty in Europe. Zacks
• Negative Sentiment: Iovance cuts staff amid a slow sales start for its TIL therapy, underlining cost pressures. Yahoo Finance
• Negative Sentiment: Shares tumble after missing Q2 expectations, trading sharply lower. MSN
• Negative Sentiment: Bay Area biotech once valued at $4.4 billion lays off a significant portion of staff, underscoring sector-wide cost cutting. MSN